Tenax Therapeutics (TENX) EBIT Margin (2011 - 2015)

Tenax Therapeutics (TENX) posted quarterly EBIT Margin of 9874.97% for Q2 2015, down 1346.87% on a QoQ basis from 682.51% in Q2 2013.

Tenax Therapeutics (TENX) EBIT Margin (2011 - 2015) Analysis & Trends

Tenax Therapeutics has reported EBIT Margin for 5 years, with the latest figure at 9874.97% in Q2 2015.

EBIT Margin for Q2 2015 came in at 9874.97%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2016 was 29548.27% (down 2868261.0% YoY), and the FY2015 annual result was 33603.73%, changed N/A from the prior year.
EBIT Margin slipped to 9874.97% in Q2 2015, from 682.51% in the prior quarter.
Over five years, EBIT Margin peaked at 10360.51% in Q1 2011 and troughed at 9874.97% in Q2 2015.
A 4-year average of 967.77% and a median of 715.64% in 2013 frame the typical range for EBIT Margin.
The largest YoY upside for EBIT Margin was 914614 bps in 2012 against a maximum downside of 1162433 bps in 2012.
A 4-year view of EBIT Margin shows it stood at 2158.73% in 2011, then jumped by 94 bps to 132.62% in 2012, then tumbled by 415 bps to 682.51% in 2013, then sank by 1347 bps to 9874.97% in 2015.
Per Business Quant data, the three most recent EBIT Margin figures were 9874.97% in Q2 2015, 682.51% in Q2 2013, and 715.64% in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Tenax Therapeutics	80.73 Mn	80.73 Mn	-	-

Download Data